Cortical Neurons In Corticobasal Degeneration is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Corticobasal Degeneration (CBD) is characterized by prominent cortical involvement, with neuronal loss and tau pathology affecting multiple cortical regions. The asymmetric cortical degeneration underlies the distinctive clinical phenotype of CBD, including apraxia, cortical sensory loss, and alien limb phenomena.
- Location: Precentral gyrus (Brodmann area 4)
- Involvement: Upper motor neuron signs, weakness
- Pathology: Neuronal loss, tau-positive inclusions
- Betz cells: Large pyramidal neurons affected
- Location: Precentral gyrus (Brodmann area 6)
- Involvement: Impaired motor planning, apraxia
- Pathology: Corticothalamic degeneration
- Connections: Supplementary motor area dysfunction
- Location: Postcentral gyrus (Brodmann areas 1, 2, 3)
- Involvement: Cortical sensory loss, sensory neglect
- Pathology: Posterior parietal involvement
- Location: Superior and inferior parietal lobules
- Involvement: Spatial disorientation, dressing apraxia
- Pathology: Dorsal stream dysfunction
- Location: Prefrontal regions (Brodmann areas 9, 10, 46)
- Involvement: Executive dysfunction, behavioral changes
- Pathology: Frontosubcortical disconnection
- Layer 5 pyramidal cells: Betz cells, corticospinal neurons
- Layer 3 pyramidal cells: Corticocortical projection neurons
- Layer 2/4 interneurons: Local circuit modulation
- Pathology: Tau inclusions, dendritic degeneration
- Parvalbumin (PV) interneurons: Fast-spiking basket cells
- Somatostatin (SST) interneurons: Dendrite-targeting cells
- VIP interneurons: Disinhibitory circuits
- Pathology: Variable vulnerability
- 4R-tau isoform: Predominant in CBD
- Astrocytic plaques: Distinctive astrocyte pathology
- Coiled bodies: Oligodendroglial tau inclusions
- Neuronal loss: Cortical layer-specific vulnerability
- Neuronal death: Asymmetric cortical atrophy
- Gliosis: Reactive astrocytosis
- Myelin loss: Subcortical white matter changes
- Spongiform changes: Neuropil vacuolation
- Akinesia/bradykinesia: Reduced spontaneous movement
- Rigidity: Axial and limb rigidity
- Dystonia: Postural deformities
- Myoclonus: Cortical myoclonus
- Apraxia: Limb apraxia,ideomotor apraxia
- Alien limb syndrome: Involuntary limb movements
- Cortical sensory loss: Two-point discrimination loss
- Neglect: Hemisensory neglect
- Executive dysfunction: Planning and organization deficits
- Language dysfunction: Non-fluent aphasia
- Behavioral changes: Disinhibition, apathy
- Aggregation: 4R-tau filament formation
- Hyperphosphorylation: Abnormal kinase/phosphatase activity
- Tau spread: Braak-like staging pattern
- Vulnerability factors: Neuronal type-specific
- Presynaptic pathology: Tau in synaptic terminals
- Postsynaptic effects: Dendritic spine loss
- Network disruption: Corticocortical disconnection
- Excitotoxicity: Glutamate-mediated damage
- Microglial activation: Chronic inflammation
- Cytokine release: IL-1β, TNF-α, IL-6
- Astrocytic involvement: Astrocytic plaques
- Levodopa: Limited benefit
- Clonazepam: For myoclonus
- Botulinum toxin: For dystonia
- Speech therapy: For dysarthria and aphasia
- Tau aggregation inhibitors: Targeting 4R-tau
- Immunotherapy: Anti-tau antibodies
- Neurotrophic support: BDNF, GDNF
The study of Cortical Neurons In Corticobasal Degeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. PMID: 23359374.
-
Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11):935-946. PMID: 12430710.
-
Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(5):263-272. PMID: 21458321.
-
McFarland NR. Corticobasal degeneration: overview and future directions. J Neurol. 2016;263(4):723-734. PMID: 26715551.
-
Cordato NJ, Halliday GM, McCann H, et al. Corticobasal syndrome vs corticobasal degeneration: a pathological and clinical comparison. J Neurol Neurosurg Psychiatry. 2011;82(10):e3. PMID: 21865294.
-
Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327-340. PMID: 21823156.
-
Boeve BF. The corticobasal syndrome. Continuum (Minneap Minn). 2016;22(5):1432-1448. PMID: 27735981.
-
Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at autopsy. J Neurol Neurosurg Psychiatry. 1998;65(4):586-595. PMID: 9771791.